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Abstract
By convention, CD4+ T lymphocytes recognize foreign and self peptides derived from internalized 
antigens in combination with MHC class II molecules. Alternative pathways of epitope production 
have been identified but their contributions to host defense have not been established. We show 
here in a mouse infection model that the CD4+ T cell response to influenza, critical for durable 
protection from the virus, is driven principally by unconventional processing of antigen 
synthesized within the infected antigen-presenting cell, not by classical processing of endocytosed 
virions or material from infected cells. Investigation of the cellular components involved, 
including the H2-M molecular chaperone, the proteasome, and gamma-interferon inducible 
lysosomal thiol reductase revealed considerable heterogeneity in the generation of individual 
epitopes, an arrangement that ensures peptide diversity and broad CD4+ T cell engagement. These 
results could fundamentally revise strategies for rational vaccine design and may lead to key 
insights into the induction of autoimmune and anti-tumor responses.
The classical MHCII processing pathway, developed chiefly through work with stable, 
globular proteins, entails: 1) engulfment of extracellular material, 2) delivery of nascent 
MHC class II (MHCII) molecules to a late endosomal compartment via its transient partner 
invariant chain (Ii), 3) catabolism of both Ii and internalized material in the endocytic 
compartment. 4) exchange of the remaining class II-associated invariant chain peptide 
(CLIP) portion of Ii for high affinity peptides and 5) trafficking of peptide/MHCII 
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complexes to the cell surface where they can trigger cognate CD4+ T cells1. MHCII 
molecules are highly polymorphic and in most cases CLIP-MHCII affinity is sufficiently 
high that CLIP-peptide exchange requires participation of a heterodimeric chaperone termed 
HLA-DM in humans and H-2M in mice2.
Viral proteins are distinct from nominal exogenous antigens in accessing intracellular 
compartments beyond the endosomal network and in interacting far more dynamically with 
cellular machinery. Indeed, studies of MHCII processing with such proteins have revealed 
several alternatives that diverge to greater or lesser extents from the classical scheme. 
Examples include: 1) a “recycling” pathway in which partially or completely disordered 
peptides derived from exogenous antigen load onto MHCII in the early endosome without 
H2-M participation3, 2) macroautophagy, which delivers cytosolic contents to the late 
endosomal network for conventional proteolysis and loading4, and 3) a pathway that 
depends upon delivery to the cytosol and participation of both the proteasome and the 
transporter associated with antigen processing (TAP)5, well established components of the 
conventional MHC class I (MHCI) processing pathway but rarely implicated in MHCII 
processing.
Because MHCII processing studies have traditionally focused on individual epitopes that are 
largely derived from exogenously provided antigens, the relative contributions of alternative 
pathways have remained unknown. In an initial attempt to address this issue, we previously 
carried out ex vivo analysis of a polyclonal influenza-specific CD4+ T cell population, 
estimating that 30–40% of the responding T cells were specific for proteasome-dependent 
epitopes5. This figure is consistent with a significant contribution from non-classical 
processing; however there were limitations to the indirect ELISpot-based approach that we 
utilized. First was the use of proteasome inhibitor at concentrations that, in retrospect, may 
have reduced protein (endogenous antigen) synthesis6. Second was the inability to determine 
whether the 30–40% fraction lay with a few dominant epitopes or reflected 30–40% of all 
the specificities involved in the response. In addition, given the existence of several 
alternative processing pathways, the other 60–70% of the response may or may not have 
been driven by classical processing. These are fundamental issues considering the 
importance of CD4+ T cells in potentiating humoral and CD8+ (cytolytic) T cell responses1 
and the predictive power of a broad CD4+ T cell response for protection against several 
human pathogens, including the hepatitis B, hepatitis C and influenza viruses7–9. Greater 
processing complexity will enhance epitope diversity and, consequently, CD4+ T cell 
participation in establishing protection. Vaccine strategies that assume sufficient CD4+ T 
cell activation via the classical pathway may engender suboptimal protection.
In order to explore both the prevalence and complexity of alternative MHCII processing, we 
turned to a mouse model of influenza infection that has provided numerous fundamental 
insights into defense against the virus10. We were guided by the principle that definitive 
information would be gained only by accounting for each of the MHCII-restricted epitopes 
that drive the influenza-specific CD4+ T cell response, subsequently exploring the 
processing requirements of each epitope through complementary in vivo- and in vitro-based 
approaches. Although our previous efforts5 led us to suspect that alternative processing 
would make more than a minor contribution, we show here that the vast majority of the 
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influenza-specific CD4+ T cell response in infected mice is driven by bona fide endogenous 
processing of antigen by the infected antigen-presenting cell (APC).
RESULTS
Influenza virions are poor MHCII processing substrates and induce weak CD4+ T cell 
responses
We reasoned that if the CD4+ T cell response to influenza is driven primarily by the 
classical pathway (defined here as conversion of internalized virions, infectious or not, to 
peptides that load onto nascent MHCII), live and inactivated influenza should elicit 
comparable responses since most encoded proteins are assembled into the virion11. Wildtype 
(WT) C57BL/6 (B6) mice, which express only the Ab MHCII molecule, were inoculated 
intranasally (i.n.) with a low dose of mouse-adapted influenza A virus, A/Puerto Rico/
8/1934 (PR8) or β-propiolactone (BPL) inactivated PR8 at a much higher dose (~4 × 106 
fold) to compensate for absence of replication12. The responding CD4+ T cells were 
analyzed by ELISpot assay with a comprehensive overlapping peptide library. Live PR8 
elicited thirteen distinct specificities, six established and seven novel (Fig. 1a, 
Supplementary Fig. 1 and Supplementary Table 1). Seven mapped to three major structural 
proteins: nucleoprotein (NP), hemagglutinin (HA), and neuraminidase (NA). Five mapped to 
the polymerase subunits (PA, PB1 and PB2) that are less prevalent in the virion11. One 
mapped to the nonstructural protein NS1, absent from the virion. In contrast, BPL PR8 
elicited only three specificities and quite weakly. No specificities unique to BPL PR8 were 
elicited (not shown), eliminating the possibility of a redistributed response. The disparity 
was not attributable to limited access to inert virions by APC nor to destruction of 
processable antigen by the inactivation procedure; intraperitoneal (i.p.), intramuscular (i.m.), 
intradermal (i.d.) and even intravenous (i.v.) delivery produced similar results as did UV and 
hydrogen peroxide inactivation of the virus (Supplementary Fig. 2–4).
In opposing the receptor binding activity of HA, NA might contribute to the low potency of 
inactivated virus by reducing antigen capture by APC11. However, elimination of NA 
activity did not enhance the response to BPL inactivated virus (Supplementary Fig. 5).
Response patterns of CD4+ T cell hybridomas to six of the specificities were consistent with 
the in vivo results; presentation by bone marrow derived dendritic cells (BMDCs) (Fig. 1b) 
and MHCII-expressing fibroblasts (Supplementary Fig. 6) was markedly, and in some cases 
absolutely, more efficient from infectious virus. Multiple independent clones for three of the 
hybridomas demonstrated comparable reactivity patterns (Supplementary Fig. 7), 
discounting individual TCR bias toward possible conformations that are unique to 
endogenously produced MHC/peptide complexes.
The data indicate that influenza virions are inherently poor processing substrates. To 
reinforce this notion, we primed and boosted WT B6 mice i.p. with high-dose BPL PR8. The 
specificities elicited in the primary response were amplified to widely varying degrees and 
four additional specificities were elicited at uniformly low levels (Fig. 1c). Five specificities 
mapping to structural proteins remained undetectable. Results were similar with prime/boost 
of UV-inactivated PR8 (data not shown). Collectively, these results indicate that processing 
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of exogenous virus is capable of producing only some of the epitopes and at efficiencies that 
range from low to marginally detectable compared to processing of biosynthesized antigen.
Inactivated virus elicits low antibody titers that poorly control a lung infection
The low CD4+ T cell response induced by inactivated virus is predicted to compromise 
induction of durable, high-titer neutralizing antibodies13,14, the hallmark of protection from 
influenza15, since “help” to B cells will be considerably diminished. We investigated this by 
immunizing WT B6 mice with two different doses of live and inactivated virus i.m., the 
standard inoculation route for the licensed subunit vaccine. Identical doses of virus were 
compared since, as we confirmed (Supplementary Fig. 8), extrapulmonary replication of 
influenza is negligible16. Induction of neutralizing antibodies, measured by 
hemagglutination inhibition (HAI) assay, was severely compromised by virus inactivation 
(Fig. 2a) and, consequently, so was ability to control a live virus challenge, with clear, 
statistically significant differences in viral lung titers three days after inoculation (Fig. 2b).
Consistent with the observed low immunogenicity of BPL PR8 and previous work17, i.p. or 
subcutaneous (s.q.) inoculation with copious quantities of a licensed split subunit vaccine, 
which cross-reacts strongly with PR8 yielded undetectable CD4+ T cell responses (Fig. 2c) 
and antibody titers (Fig. 2d) were significantly lower than those elicited by live PR8 i.p.
Active infection does not enhance virion presentation
The superior immunogenicity of infectious virus could have been due to upregulation of 
antigen processing via the inflammatory signals triggered by viral replication18. To test this 
possibility, we inoculated WT B6 mice with a mixture of inactivated PR8 and infectious 
non-cross-reactive B/Lee/1940 (B/Lee) influenza. Despite inducing a robust autologous 
response, infectious B/Lee did not enhance the anti-PR8 response (Fig. 3). Similar results 
were obtained following co-inoculation i.m., i.d. (Supplementary Figs. 2b and c) and i.n. 
(not shown). We observed the same outcome in vitro using BMDCs and the hybridoma 
panel where we were able to ensure, through the use of sufficiently high multiplicities of 
infection, internalization of both viruses by the same APC. In no case was presentation from 
BPL PR8 enhanced by the presence of infectious B/Lee and in several cases presentation 
was diminished (Supplementary Fig. 9).
Bona fide endogenous processing is the main driver of CD4+ T cell stimulation
Skewing toward presentation of biosynthesized antigen could be due to bona fide 
endogenous processing by the infected cell or transfer to an uninfected APC of subviral 
material that is more easily processed via the exogenous pathway than whole virions. To 
assess the relative contributions of these two general mechanisms in vitro, we infected 
MHCII-negative (MHCII−)donor cells and combined them with uninfected BMDCs, the T 
hybridoma panel and neutralizing antibody to prevent infection of the recipient APCs. Only 
one epitope (NP-47) demonstrated relatively robust presentation via transfer (Fig. 4a), and 
this was at least 16-fold less efficient than presentation by directly infected BMDCs. Use of 
BMDCs from H2-M-deficient mice as recipients demonstrated that presentation via transfer 
of all six epitopes is H-2M-dependent (Supplementary Fig. 10), suggesting that processing 
of transferred antigen is typically via the classical pathway.
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To assess the relative contributions of direct presentation and transfer in vivo we utilized 
three independent approaches. First, magnetic bead-isolated MHCII+ cells from the lungs of 
infected mice, which migrate to regional lymph nodes to initiate T cell responses19, were 
separated by FACS into surface HA+ (infected) and HA− pools. Twofold serial dilutions of 
the otherwise unmanipulated pools were co-incubated with polyclonal flu-specific CD4+ T 
cells (Fig. 4b) or individual T hybridomas (Fig. 4c). If antigen transfer were a robust 
mechanism in vivo, then the MHCII+HA− pool should demonstrate strong stimulatory 
capacity. However, consistent with the in vitro assay (Fig. 1b), the HA+ pool was 
substantially more potent (8–16-fold) while the pools demonstrated similar presentation 
abilities when pulsed with exogenously provided synthetic peptide. Results were similar for 
cells collected 3 d (shown) and 1 d (not shown) after infection.19 This approach likely 
overestimates the contribution of antigen transfer since most flu infected cells do not express 
the full complement of viral proteins20 and, indeed, we confirmed that a fraction of the HA− 
pool stains positive for NP and NS1 (not shown). The deleterious impact of cell 
permeabilization on antigen presentation precluded us from staining for internal proteins 
during the sorting procedure.
In our second approach, we infected BALB/c and B6 splenocytes with influenza, UV 
irradiated them to prevent subsequent release of infectious progeny, verifying inactivation 
by plaque assay (not shown), and adoptively transferred them by i.p. injection into naive 
BALB/c and B6 recipients. The B6→B6 transfer resulted in an influenza-specific CD4+ T 
cell response as detected by peptide-based ELISpot assay while the BALB/c→B6 
configuration, which precludes direct presentation, did not (Fig. 4d).
In the third approach, i.n. or i.p injection of a PR8-infected cell lysate yielded no detectable 
CD4+ T cell response even when co-inoculated with live B/Lee (not shown). All three 
outcomes support our hypothesis that directly infected APCs carrying out bona fide 
endogenous MHCII antigen processing are the main drivers of the CD4+ T cell response.
PR8 presentation in vivo involves H2-M-dependent and -independent mechanisms
We initially explored the endogenous processing mechanisms underlying presentation of the 
thirteen PR8 epitopes with a panel of knockout mice on the H-2b background. In earlier 
studies, we had identified an Ed-restricted epitope within HA that is presented by recycling 
MHCII independent of H-2M expression. This behavior was attributable to location of the 
epitope in the stalk region of HA that unfolds in response to acidification shortly after 
internalization, rendering the epitope available for MHCII binding within the early 
endosome. We anticipated that none of the thirteen Ab-restricted epitopes would be 
presentable in the absence of H-2M because the one epitope within HA (HA-16) is not 
located in the stalk region and none of the other flu proteins is known to undergo unfolding 
in the early endosome. In addition Ab has a high affinity for CLIP21 and participation of 
H-2M in classical, late endosomal loading appears to be mandatory22. Nevertheless, six 
specificities were robustly elicited in H2-M-deficient mice (Fig. 5a). Indeed, all responses 
were substantially higher than in WT mice, possibly due to H2-M-mediated suppression as 
described for an HLA-DQ2-restricted epitope23. A similar peptide-based analysis of the 
CD4+ T cell response to ectromelia virus has revealed a much lower frequency of H2-M-
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independent presentation (M. Mendonca and B. DeHaven, unpublished), discounting 
anomalous hyperreactivity of H2-M-deficient mice to viral infection. The results suggest 
processing schemes for these six epitopes that do not entail peptide loading in the late 
endosome. In support of this, nearly the same reactivity pattern was elicited in (Cd74 
encodes Ii) mice although, compared to H2-M-deficient mice, T cell expansions were lower 
(Fig. 5b). Of particular note, all three of the epitopes that were presentable in vivo from 
inactivated virus (NP-45, NP-52 and NA-41) fall into this H2-M-independent category. 
Therefore, none of the thirteen epitopes is processed in vivo solely, or even predominantly, 
via the classical pathway as defined, and the alternatives involve both H2-M-dependent and 
-independent mechanisms.
We also previously described two Ed-restricted epitopes whose endogenous presentation 
depended upon TAP function5. Immunization of TAP-deficient vs. WT mice in the H-2Ab 
background and normalization of the ELISpot data revealed partial reduction of the 
responses to two epitopes responses to two epitopes (NP-52 and HA-16, Fig. 5c). However, 
CD8-deficient mice also displayed selectively diminished responses to the same two 
epitopes (Fig. 5d), suggesting that TAP-dependent CD8+ T cell activity in some way 
enhances responses to these two epitopes. A lack of TAP dependence for any of the Ab-
restricted epitopes suggests that TAP participation in MHCII processing may be allele 
specific. In addition, our findings are in contrast with the recent report that absence of TAP 
profoundly alters the Ab-bound peptidome24.
In vitro analyses reveal additional endogenous processing heterogeneities
Further exploring underlying processing mechanisms, we utilized the hybridoma panel to 
investigate participation by the proteasome. In both BMDCs and a MHCII-expressing 
fibroblast line, endogenous presentation from infectious virus of two epitopes (NP-47 and 
NA-25) was potently reduced by treatment versus mock treatment with the proteasome 
inhibitor exoxomicin under conditions of persisting protein synthesis (Supplementary Fig. 
11), with only stimulation from input (exogenous) virus remaining (the stimulating activities 
of BPL PR8 providing these reference points). Presentation from inactivated virus was 
uniformly unaffected (Figs. 6a and b). In the case of the NP-45 epitope, inhibition of 
endogenous presentation was again complete in the fibroblast line but only partial in 
BMDCs, suggesting both dependent and independent endogenous pathways in BMDCs. 
Thus, for half of the six epitopes, derived from both cytosolic and glycoprotein antigens, and 
including one that can also be generated via exogenous presentation in vivo (NP-45), robust 
presentation is proteasome-dependent. This frequency is in line with our previous analysis of 
a polyclonal influenza-specific CD4+ T cell population5 but clearly additional study is 
needed to determine the actual fraction. Since macroautophagy does not appear to be 
operative in the processing of PR825,26, novel mechanisms are likely involved in the 
endogenous processing of the remaining three epitopes (HA-16, NA-41 and NA-110).
Seeking additional mechanistic insight, we investigated generation of the NA-25 and NA-41 
epitopes, both being constrained within native NA by disulfide bonds. The NA-110 epitope, 
which lacks a cysteine residue, provided an internal control. Gamma-interferon induced 
lysosomal thiol reductase (GILT) can be critical for processing of exogenously obtained, 
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disulfide bonded antigens27 but has not been implicated in endogenous processing. Indeed, 
endogenous processing of both epitopes by BMDCs was strongly GILT-dependent (Fig. 6c). 
Expansion of these two specificities was also selectively reduced in GILT-deficient mice 
(Supplementary Fig. 12a), but only partially, suggesting that GILT-independent processing 
mechanisms are operative in vivo. The relevant GILT activity appears to reside in the 
endosomal compartment since endogenous presentation of both epitopes was strongly 
inhibited by primaquine, a compound that disrupts endosomal trafficking3, while 
presentation of the NA-110 epitope was unaffected (Fig. 6d). Furthermore, presentation of 
exogenously provided disulfide-constrained synthetic peptides was also GILT-dependent 
(Fig. 6e and Supplementary Fig. 13). A second potential site of GILT action we considered 
was the endoplasmic reticulum, where GILT might mediate ERAD-driven reduction of full-
length NA in order to facilitate retrograde translocation to the cytosol for conventional 
MHCI-like processing. However, this function should impact NA presentation globally and 
presentation of NA-110 is not GILT-dependent. Furthermore, responses to several MHCI-
restricted epitopes within NA are not compromised in GILT-deficient mice (indeed, they are 
enhanced, Supplementary Fig. 12b). The results suggest novel pathways that pair 
proteasome-dependent and -independent processing in the cytosol with GILT-dependent 
processing in the endosome (Supplementary Fig. 14) via an as yet unidentified transport 
mechanism since neither TAP (Fig. 5c) nor macroautophagy25,26 appear to be involved. This 
analysis expands the striking heterogeneity in endogenous antigen processing evidenced in 
earlier figures. Indeed, when the various parameters examined here are compiled, each of 
the six epitopes is unique. Collectively, results suggest the existence of an endogenous 
processing network that is uniquely traversed in the generation of each epitope. Factors such 
as proteolytic susceptibility of the epitope and subcellular location of the parent protein may 
determine the route that leads to productive processing. The open-ended peptide binding 
groove of MHCII, which obviates the need for precise processing, would facilitate such an 
arrangement.
DISCUSSION
The outcomes reported here are strongly at odds with the prevailing model of MHCII 
processing. We attribute this to: 1) historical focus by the field on purified proteins, 
originally developed to study delayed-type hypersensitivity responses28, and having 
restricted access to extra-endosomal compartments, 2) the greater complexity of viruses that 
renders them less amenable to classical processing and more disposed to alternatives, owing 
to production of antigen within the APC, 3) the common practice of studying epitopes in 
isolation, which precludes the “accounting” approach that was taken here, and 4) the 
generation of many viral epitopes by more than one pathway, particularly appreciable in 
vitro (Fig. 1b), which could potentially confine scope of investigation to exogenous 
processing.
Live influenza vaccines are generally more protective than inactivated preparations, 
particularly in first time vaccinees29,30, and live vaccines in general require fewer 
immunizations to attain durable protection1. The engagement of multiple, non-redundant 
processing routes, would serve to maximize peptide diversity, thereby ensuring a broadly 
reactive CD4+ T cell response that is important for protection against several human 
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pathogens, including influenza7–9, and perhaps many others, through the potentiation of both 
cellular and humoral immunity. It should therefore be of benefit to incorporate this principle 
into rational vaccine design, bearing in mind that processing pathway distribution will likely 
differ for each pathogen based upon structure, replication strategy and tropism. Finally, in 
light of findings reported here, and with autoimmune disorders and cancer immunotherapy 
in mind, greater exploration of non-classical MHCII processing of self-antigens seems 
warranted.
Methods
Peptides
The following reagents were obtained through the NIH Biodefense and Emerging Infections 
Research Resources Repository, National Institute of Allergy and Infectious diseases 
(NIAID), NIH: Peptide Array, Influenza Virus A/Puerto Rico/8/1934 (H1N1) 
Hemagglutinin Protein, NR-18973; Peptide Array, Influenza Virus A/Puerto Rico/8/1934 
(H1N1) Neuraminidase Protein, NR-19257; Peptide Array, Influenza Virus A/New York/
348/03 (H1N1) PB1 Protein, NR-2617; Peptide Array, Influenza Virus A/New York/348/03 
(H1N1) PB2 Protein, NR-2616; Peptide Array, Influenza Virus A/New York/348/03 (H1N1) 
Nucleocapsid Protein, NR-2611; Peptide Array, Influenza Virus A/New York/444/01 
(H1N1) Nonstructural Protein 1, NR-2612; Peptide Array, Influenza Virus A/New York/
348/03 (H1N1) Nonstructural Protein 2, NR-2615; Peptide Array, Influenza Virus A/New 
York/348/03 (H1N1) Matrix Protein 1, NR-2613; Peptide Array, Influenza Virus A/New 
York/348/03 (H1N1) Matrix Protein 2, NR-2614; Peptide Array, Influenza Virus A/New 
York/348/03 (H1N1) PA Protein, NR-2618, Peptide Array, Influenza Virus A/Brisbane/
59/2007 (H1N1) Hemagglutinin Protein, NR-18970. Lyophilized peptides were 
reconstituted in dimethyl sulfoxide (DMSO; Sigma) and stored at −20 °C. Synthetic 
peptides (NA-25, NA-41, NA-110) were pre-treated with 0.5 mM 2-Mercaptoethanol (2-
ME) for 30 minutes at 37 °C to allow for reduction of disulfide bonds.
Influenza viruses
Influenza A virus, A/Puerto Rico/8/1934 (PR8), subtype H1N1, and Influenza B virus, 
B/Lee/1940 (B/Lee) were grown, harvested, titered, and plaqued from isolates as described 
previously31,32. One hemagglutinating unit (HAU) of live PR8 virus ≈1.5 ×105 plaque 
forming units, titered as previously described32. Viruses were inactivated using either β-
propiolactone33 (BPL; Sigma) or UV light34. In the BPL protocol, allantoic fluid containing 
virus was buffered in HEPES (0.1 M) and treated with BPL (0.1%) at 4 °C overnight. The 
next day, the prep was incubated at 37 °C for two hours to inactivate BPL. Hemagglutinin 
activity was determined by HAU titer using chicken red blood cells35. Heat inactivation of 
NA and measurement of NA activity using 4-MUNANA (Sigma) were as previously 
described36. The following reagents were obtained through the NIH Biodefense and 
Emerging Infections Research Resources Repository, NIAID, NIH: Influenza A Virus, A/
Brisbane/59/2007 (H1N1), NR-12282; Fluzone® Influenza Virus Vaccine, 2006–2007 
Formula, NR-10483; Fluzone® Influenza Virus Vaccine, 2008–2009 Formula, NR-17423.
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Primary APCs and cell lines
Immature bone marrow-derived dendritic cells (BMDCs) were generated as previously 
described31 with the following modifications: media changes were performed every 3 days 
and BMDCs were harvested on day 8. The DC2.4 cell line was maintained in RPMI 
(Corning Cellgro) supplemented with 10% FBS (Gibco), 1× penicillin/streptomycin(Fisher 
Scientific), 1× L-glutamine (Fisher Scientific), and 0.05 mM 2-mercaptoethanol (2-ME; 
Gibco). The following reagent was obtained through the NIH Biodefense and Emerging 
Infections Research Resources Repository, NIAID, NIH: Mouse Interferon Gamma 
(MuIFN-γ), NR-3081. For ELISpot assays, DC2.4 were pretreated with 2 International Units 
(IU)/ml MuIFN-γ for 48 hours to upregulate MHCII expression. B6 fibroblast cell line has 
been described previously37. Class II, major histocompatibility complex, transactivator 
(CIITA)-transduced B6 fibroblasts, MC57G (ATCC), L929 (ATCC), and I-Ab transduced 
L929 (L-IAb) cell lines were maintained in DMEM (Corning Cellgro) supplemented with 
10% FBS and 0.05 mM 2-ME. All cell lines were periodically surveyed for mycoplasma 
using a commercial detection kit (Agilent technologies, catalog no. 302109)
T cell hybridomas
LacZ-inducible CD4+ T cell hybridomas, which express β-galactosidase upon recognition of 
peptide-MHCII complexes, were generated for NP-45, NP-47, HA-16, NA-25, NA-41, and 
NA-110 epitope specificities following previously described methods31,38. T cell 
hybridomas were maintained in RPMI supplemented with 10% FBS, 1× Penicillin/
Streptomycin, 1× L-glutamine and 0.05 mM 2-ME. Activation was measured by detection of 
fluorometric β-galactosidase substrate methyl-umbelliferyl-β-D-galactoside (MUG; Sigma) 
as previously described39.
Mice
6–8 week old female C57BL/6, BALB/c, CD8−/− Tap1−/− (B6.129S2-Tap1tm1Arp/J), 
(B6.129S2-Tap1tm1Arp/J) (Jackson Laboratories), C57BL/6 H2-DMa−/− (Jackson 
Laboratories and provided by P. Roche), Ifi30−/− (provided by K. Hastings,) and Cd74−/−40 
(provided by Guo-Ping Shi,) mice were utilized in all experiments. Colonies were 
maintained by Thomas Jefferson University Office of Laboratory Animal Services. Animal 
numbers were empirically determined to optimize numbers necessary for statistical 
significance. Exclusion criteria for mouse studies were weight loss in excess of 20% and no 
mice were excluded from this study. Animal studies were not randomized and investigators 
were not blinded for this study. All experimental protocols were preapproved by the Thomas 
Jefferson University Institutional Animal Care and Use Committee (IACUC). Numbers of 
mice used in each experiment were the minimums needed to obtain sufficient cell numbers 
for in vitro assays, statistical significance in in vivo assays and to demonstrate 
reproducibility; these were consistent with usage outlined in the IACUC-approved protocols.
Peptide-based ELISpot assays
Mice were primed intranasally with the following viruses at indicated doses: live PR8 (0.001 
HAU), BPL-inactivated PR8 (3800 HAU). Groups of 3 mice were primed per condition. 
Mouse spleens were harvested 10–12 days post-priming, pooled, and CD4+ or CD8+ T cells 
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were purified using Dynal CD4 or CD8 Negative Isolation Kits according to manufacturer’s 
instructions (Invitrogen). BMDC or MuIFN-γ-activated DC2.4 were used as APC and co-
cultured overnight with purified CD4+ T cells (105 per well in all cases) in the presence of 
indicated peptides and screened for production of IFN-γ as a readout of T-cell activation. 
Overlapping peptide libraries were screened in triplicate as either matrixed peptide pools 
(containing 8–12 peptides/well)41 or individual peptides at a final concentration of 10 μg/ml. 
For all ELISpot assays, baselines were calculated as 2s.d. above background.
Fluzone immunogenicity
B6 mice were primed i.p. with 4 HAU of live PR8, 22.5 μg of H1 Fluzone 2006–2007 
formula i.p., or 22.5 μg of H1 Fluzone 2006 -2007 formula s.c. 12 d later, cytokine ELISpot 
assays were performed for detection of IFN-γ -secreting CD4+ T cells in response to 
individual influenza peptides. CD4+ T cell immunogenicity of the H1 HA molecule 
contained in the Fluzone 2006–2007 preparation was confirmed (Supplementary Fig. 15).
In vivo cross priming studies
Adapted from Norbury et al42. Splenocytes from two naive female B6 or BALB/c mice were 
first infected with live PR8 virus for 1 hour at 37 °C in serum-free medium. To allow for 
expression of viral proteins, infected cells were cultured overnight at 37 °C and cells were 
UVB irradiated for 15 minutes. Cells were harvested and washed with PBS. Groups of three 
female B6 mice were primed intraperitoneally with 5×106 PR8 infected B6 or BALB/c 
splenocytes in a total volume of 200 μL per mouse. Ten days post-immunization, spleens 
were harvested and CD4+T cells were isolated to perform ELISpot assays. MuIFN-γ-
activated DC2.4 were used as APC and pulsed with individual peptides at a final 
concentration of 10 μg/ml. Results with individual peptides were summed and mean 
standard deviation for the total was determined by calculating the square root of the 
averaged variances.
Protection studies
Sets of 7 female B6 mice were primed intramuscularly either with PBS or 0.1 or 0.3 HAU 
live or BPL inactivated PR8. Mice were bled at days 14 and 26 to perform serum HAI 
antibody titers using chicken red blood cells (RBCs). Mice were challenged intranasally 
with 20 HAU live PR8 at day 28 and lungs were harvested 3 days post challenge. Harvested 
lungs were processed using gentleMACSdissociator and live virus was titered by plaque 
assay from homogenates. Control of a heterologous challenge, indicating breadth of 
neutralization capability, was not investigated in these studied.
i.p. lavage and virus titer assay
B6 mice were injected i.p. with 1 HAU of live PR8 on days 0, 1, 2, or 3. Mice were 
subsequently sacrificed and peritoneal washes were performed by i.p. injection of 1 ml cold 
PBS. Lavage fluid was harvested on ice, pre-cleared of cells by centrifugation and directly 
assessed for infectious virus (plaque-forming units, p.f.u.) in a viral plaque assay32.
Miller et al. Page 10
Nat Med. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
ELISA
Serum was collected from primed mice by retro-orbital eye bleeding and analyzed for IgG 
titer by ELISA. Briefly, serum was serially diluted in PBS supplemented with 1% low-IgG 
bovine serum albumin (BSA; Gemini Bio-Products), ranging from 1:500 to 1:32,000, and 
incubated in high binding EIA/RIA plates (Corning) pre-coated with 2 HAU of PR8. Plates 
were then washed with PBS + 0.01% Tween (PBST) and incubated with peroxidase labeled 
anti-mouse IgG (H+L) (Vector Laboratories, catalog no. PI-2000) at 1:1500 dilution in 
PBS/BSA (1%). Plates were developed using ABST Peroxidase Substrate (KPL) and read at 
detection wavelength of 405 nm.
In vitro antigen presentation assays
Epitope-specific LacZ-inducible T cell hybridomas were co-cultured in the presence of 
various antigen presenting cells (APC) pulsed with infectious or inactivated virus as 
described previously31. For antigen transfer assays, L929 cells were infected with live PR8 
(1, 16 and 256 HAU) for 45 minutes and then washed twice to remove remaining virus. 
They were subsequently co-cultured overnight (18–20 h) with uninfected BMDC and T cell 
hybridomas. For proteasome inhibition assays, APCs were pre-treated with epoxomicin 
(Boston Biochem) for 15 minutes and washed once before infection with virus. To assess the 
effect of epoxomicin on protein synthesis, treated APCs were cultured for 18–20 h, stained 
with primary anti-HA IgG (H28-E23) antibody sup and secondary anti-mouse IgG FITC at 
0.5 μg per test (eBioscience, catalog no. 11–4011), and analyzed by flow cytometry for 
surface expression of PR8 HA. Acquisition was performed on a FACS calibur. Baseline 
MFIs, calculated as 2s.d.above background, were subtracted from individual conditions. 
Amino acid supplementation43 did not alter the dose response curve in BMDCs (not shown). 
In assays involving primaquine-treated APCs, B6 fibroblasts were pre-treated with the 
compound for 30 minutes before infection with live virus. APCs were maintained overnight 
in the presence of primaquine, then fixed with 0.3% paraformaldehyde in 1.5 × HBSS for 15 
minutes at room temperature and washed twice with complete medium before co-culturing 
with T cell hybridomas. For disulfide-bonded peptide assays, synthetic peptides (New 
England Peptides) were stored in DMSO (an oxidizing agent) allowing for disulfide-
homodimerization to form between the single cysteine residues in each peptide. APC were 
then pulsed with varying amounts of disulfide-constrained peptides before co-culturing with 
T cell hybridomas.
Ex vivo cross-presentation assay
Groups of 5 female B6 mice were immunized i.n. with 128 HAU infectious PR8 or B/Lee. 3 
d.p.i., mouse lungs were perfused with 5 ml cold PBS and harvested. Lung tissue fragments 
were collected to gentleMACS C tubes (MiltenyiBiotec) and enzymatically digested with 
Dispase II (9.4 U/ml) (Roche) and Collagenase A (50 mg/ml) (Roche) in serum-free RPMI 
media at 37 °C for 45 min under slow mixing. Tubes were transferred to 
gentleMACSDissociator (MiltenyiBiotec) and the protocol was run according to the 
manufacturer’s recommendations. Cell clumps were removed with a cell strainer. ACK lysis 
buffer (Life Technologies) was used to lyse any remaining RBCs. Lung cells were enriched 
for MHCII+ cells using anti-MHCII bead separation (MiltenyiBiotec, catalog no. 
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130-052-401). Cells were blocked with mouse Fc block (BD Biosciences) and stained with 
Alexa Fluor 647-conjugated anti-HA (mouse MAb H36-26) at 1:100 dilution. Surface HA 
cells were sorted using FACS (BD FACSAria II). Doubling serial dilutions of APC were 
then co-incubated with a polyclonal flu-specific CD4+ T cell in an ELISpot assay (96 well 
plate format, starting at 105 APC per well and a constant 1 × 105 CD4+ T cells per well) or 
individual T cell hybridomas in a MUG assay (384 well plate format, starting at 5 × 104 
APC per well and a constant 1 × 104 T cell hybridomas per well). Polyclonal flu-specific 
CD4+ T cell were isolated using Dynal CD4 Negative Isolation Kits according to 
manufacturer’s instructions (Invitrogen) from mice primed with 0.003 HAU live PR8 i.n. 12 
d.p.i.. To verify if surface-HA sorted cells have equal antigen presentation, processed/
purified lung cells (105 per well) were pulsed with a VACV-specific peptide identified as an 
H-2Ab-restricted epitope by M. Mendonca and B. DeHaven (unpublished, peptide sequence 
LTGYAPVSPIVIART, 0.02 μg/ml) and co-incubated with VACV-primed CD4+ T cells (1 × 
105 per well) in an ELISpot assay. VACV-specific CD4+ T cell were isolated 12d after 
priming with 1 × 105 p.f.u. live VACV-WR i.p. using Dynal CD4 Negative Isolation Kits. 
For all ELISpot assays, baselines were calculated as 2s.d. above background.
Statistical Analyses
All samples represent technical replicates, n = 3, unless noted. Data are presented as mean ± 
s.d. Reported P values were calculated using a one-tailed Student’s t-test or two-way 
ANOVA and post-hoc pairwise comparisons with Bonferroni correction (GraphPad Prism 
Software), and the data met the assumptions of the test. P values are indicated by the 
following symbols: *P< 0.05, **P< 0.01, ***P< 0.0005 and n.s.= not significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Impact of virus inactivation on in vivo and in vitro epitope-specific CD4+ T cell responses to 
PR8. (a) B6 (WT) mice were primed i.n. with live PR8 (0.001 hemagglutination units 
[HAU], gray bars) or BPL-inactivated PR8 (BPL PR8, 3800 HAU, black bars). 12 days 
later, IFN-γ-secreting CD4+ T cell specific for the indicated peptides (sequences in 
Supplementary Table 1) were quantified by ELISpot (b) BMDCs were pulsed with either 
live PR8 or BPL PR8 and co-cultured with CD4+ T cell hybridomas of the indicated 
specificities Virus amounts from light to dark, respectively: 1, 16, 256 HAU. (c) B6 mice 
were primed intraperitoneally with 3800 HAU BPL PR8 on day (d) 0 and boosted with the 
same dose on d21. On day 28, CD4+ T cells were purified from harvested spleens and 
responses to individual influenza peptides were quantified by ELISpot assay. Results were 
similar with prime/boost of UV-inactivated PR8 (data not shown).100,000 CD4+ T cells/
well were cultured in all ELISpot assays shown here and elsewhere. Female mice were used 
in all experiments. (a, b, c) (representative of three independent experiments performed in 
triplicate). Data are presented as mean ± s.d. Background [(a, c) mean DMSO ± (2 × 
standard deviation (s.d.)); (b) mean uninfected APC] was subtracted from the experimental 
group results. MUG, methyl-umbelliferyl-β-D-galactoside
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Figure 2. 
Vaccination with inactivated PR8 induces low levels of influenza-specific neutralizing 
antibodies, which poorly control virus replication. The licensed split subunit vaccine 
similarly displays poor CD4+ T cell and B cell immunogenicitty. (a) Mice were primed i.m 
with 0.1 HAU live PR8 (▲) (n = 7), 0.1 HAU BPL PR8 (▼) (n = 10), 0.3 HAU live PR8 (▲) 
(n = 7), or 0.3 HAU BPL PR8 (▼) (n = 7) and serum HAI antibody titers were quantified on 
d26 (left graph). (b)They were then challenged i.n with 20 HAU live homologous PR8. Live 
virus was titered by plaque assay from lung homogenates 3 days post immunization (d.p.i.). 
(c) B6 mice were primed i.p. with 4 HAU live PR8 (white bars), 22.5 μg H1 Fluzone 2006–
2007 formula i.p. (dark gray bars, not visible), or 22.5 μg H1 Fluzone 2006–2007 formula 
s.c. (black bars, not visible). This is higher than the dose administered to humans (15 μg HA 
each). 12 days later, cytokine ELISpot assays were performed for detection of IFN-γ-
secreting CD4+ T cells in response to individual influenza peptides. (d) Serum IgG titer to 
PR8 was determined by ELISA. Sera were collected on d12 from the same mouse groups - 
live PR8 i.p. (◇), Fluzone i.p. (■), Fluzone s.c. (▲) - inoculated in panel (c) and sera from 
naive (×) mice were used as controls. (c) (representative of two independent experiments 
performed in triplicate) (d) (representative of two independent experiments performed in 
duplicate, error bars covered by symbols). Data are presented as mean ± s.d. Background 
(mean DMSO + 2s.d.) was subtracted from the experimental group results. Statistical 
significance was tested (for a and b) by one-tailed Student’s t-test and (for d) P < 0.0001 by 
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two-way ANOVA and post-hoc pairwise comparisons with Bonferroni correction.***P < 
0.005, * P < 0.05.
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Figure 3. 
Co-inoculation with infectious B/Lee does not enhance the CD4+ T cell response to BPL 
PR8. (a) B6 mice were primed intraperitoneally with 4 HAU live PR8 (white bars), 4800 
HAU BPL PR8 (light gray bars), or 4800 HAU BPL PR8 and 400 HAU live B/Lee (dark 
gray bars). 12 days later, cytokine ELISpot assays were performed for detection of IFN-γ-
secreting CD4+ T cells in response to individual influenza peptides. (b) To verify efficient 
B/Lee priming, BMDCs were pulsed with either 4 HAU live PR8 or 4 HAU live B/Lee (x-
axis) and co-cultured with purified CD4+ T cell from each priming condition. Data are 
representative of two independent experiments performed in triplicate. Data are presented as 
mean ± s.d. Background (DMSO ± 2s.d.) was subtracted from the experimental group 
results. Statistical significance (for a) was tested by one-tailed Student’s t-test.
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Figure 4. 
Relative contributions of direct endogenous presentation and antigen transfer in vitro and in 
vivo. (a) MHCII− L929 cells were infected with live PR8 and co-cultured with uninfected 
BMDCs and T hybridomas (“Antigen [Ag] Transfer”). For the comparator (“Direct”), 
BMDC were pulsed with live PR8 under the same conditions as in Fig. 1b. (b) B6 mice were 
infected with PR8 i.n. (128 HAU) and 3 d.p.i., MHCII+ cells were isolated from 
homogenized lungs, flow-sorted into HA+ and HA− cell pools and combined in an ELISpot 
assay with PR8-immune (main panel) or vaccinia virus (VACV)-immune (inset) CD4+ T 
cells. Inset: The HA+ and HA− pools were pulsed with a VACV-derived peptide and co-
incubated with a VACV-specific polyclonal CD4+ T cell population (c) MHCII+HA+ and 
MHCII+HA− cells, prepared as described in b were co-cultured with T hybridomas 
overnight. (d) Naive splenocytes from B6 or BALB/c donor mice were infected with 50 
HAU live PR8 per 1×106 cells, cultured overnight and then UV irradiated to prevent 
transmission of infectious virus. B6 mice were immunized i.p with 5 ×106 infected cells. 
11d later, IFN-γ-producing CD4+ T cells were quantified by ELISpot assay.
(a,c & d) representative of three and (b) two independent experiments performed in 
triplicate. Data are presented as mean ± s.d. Background [(a) mean uninfected APC; (b & c) 
MHC-II+ cells from B/Lee inoculated mice, (d) mean DMSO] was subtracted from the 
experimental group results.(b & d). Statistical significance was tested by one-tailed 
Student’s t-test.*** P < 0.0001.(d) Results with individual peptides were summed and mean 
standard deviation for the total was determined by calculating the square root of the 
averaged variances. MUG, methyl-umbelliferyl-β-D-galactoside
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Figure 5. 
Selective H-2M-, and Ii-independent presentation in vivo. WT (gray bars), H2-DMa−/−(a), 
Cd74−/−(b), TAP1−/−(c) and CD8a−/−(d) (all black bars) mice were primed with live PR8 
and analyzed by IFN-γbased ELISpot assay as described for Fig. 1a. For c and d, the data 
were normalized as % total response.) (c, inset) In the same ELISpot assay, whole 
splenocytes from WT (white bar), TAP-deficient (gray bar), or CD8-deficient (black bar) 
mice were pulsed with TAP-dependent MHC-I restricted influenza epitope, NP (366–374). 
(a) (representative of three independent experiments performed in triplicate). (b,c,d)
(representative of two independent experiments performed in triplicate). Data are presented 
as mean ± s.d. Background (DMSO + 2s.d.) was subtracted from the experimental group 
results. Statistical significance was tested by one-tailed Student’s t-test. *P<0.05; **P<0.01.
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Figure 6. 
Involvement of the proteasome and GILT in endogenous processing. B6 fibroblasts (a) and 
BMDCs (b) were pre-treated with the indicated concentrations of epoxomicin (epox) or 
DMSO, pulsed with 10 HAU of live PR8 or BPL PR8 (fibroblasts) or 1 HAU of live PR8, 1 
HAU BPL PR8 or 10 HAU BPL PR8 (BMDCs), and co-cultured with the indicated CD4+ T 
cell hybridomas. For BMDC data, responses to 1 HAU BPL PR8 (negligible for all but the 
NP-47 hybridoma) were subtracted from responses to 1 HAU live PR8, which facilitated 
comparison between groups. Because proteasome inhibition can compromise protein 
synthesis6, particularly in the case of BMDCs, complicating interpretation of results, we first 
identified appropriate concentrations of epoxomicin by flow cytometry (Supplementary Fig. 
12). (c) BMDCs (WT or GILT−/−) were pulsed with increasing amounts of live PR8 (1, 50, 
250 HAU; light to dark columns) and co-cultured with the indicated CD4+ T cell 
hybridomas. (d) B6 fibroblasts were pre-treated with the indicated concentrations of 
primaquine (pq) and pulsed with 1 HAU live PR8. APC were fixed after 18 hours and co-
cultured with the indicated CD4+ T cell hybridomas. (e) BMDCs (WT or GILT−/−) were 
pulsed with increasing amounts of disulfide-constrained synthetic peptides and co-cultured 
with the indicated CD4+ T cell hybridomas. (a,b,c,e) (representative of three independent 
experiments performed in triplicate). (d)(representative of two independent experiments 
performed in triplicate).Data are presented as mean ± s.d. Background [(a,b,c,d) mean 
uninfected APC; (e) mean DMSO-pulsed APC] was subtracted from the experimental group 
results.
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